首页> Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners> Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study.

Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study.

导出原文传递

翻译打印收藏纠错

第一作者： H,Arzu Yaşar

第一单位： Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.

作者： H,Arzu Yaşar ^[1] ; Hande,Turna ^[2] ; Ece,Esin ^[3] ; A,Murat Sedef ^[4] ; Ali,Alkan ^[5] ; Berna,Oksuzoglu ^[3] ; Nuriye,Ozdemir ^[6] ; Ma Nahit,Sendur ^[7] ; Ahmet,Sezer ^[4] ; Saadettin,Kılıckap ^[8] ; Gungor,Utkan ^[1] ; Hakan,Akbulut ^[1] ; Ismail,Celik ^[8] ; Huseyin,Abalı ^[9] ; Yuksel,Urun ^[1]

作者单位： Medical Oncology, Ankara University School of Medicine, Ankara, Turkey. ^[1] Medical Oncology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey. ^[2] Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey. ^[3] Medical Oncology, Baskent University Adana Hospital, Adana, Turkey. ^[4] Medical Oncology, Osmaniye State Hospital, Osmaniye, Turkey. ^[5] Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey. ^[6] Medical Oncology, Faculty of Medicine, Ankara Atatürk Education and Research Hospital, Yıldırım Beyazıt University, Ankara, Turkey. ^[7] Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. ^[8] Medical Oncology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey. ^[9]

关键词 Ipilimumab mucosal melanoma prognostic factors uveal melanoma